Phentermine, Sibutramine and Affective Disorders

키워드

참고문헌 (59)

1. Berkowitz RI, "Obesity, psychiatric status, and psychiatric medications", Psychiatr Clin North Am, 34, pp.747~764 (2011)
2. de Wit L, "Depression and obesity: a meta-analysis of community-based studies", Psychiatry Res, 178, pp.230~235 (2010)
3. Fagiolini A, "Prevalence of obesity and weight change during treatment in patients with bipolar I disorder", J Clin Psychiatry, 63, pp.528~533 (2002)
4. Keck PE, "Bipolar disorder, obesity, and pharmacotherapy- associated weight gain", J Clin Psychiatry, 64, pp.1426~1435 (2003)
5. McElroy SL, "Correlates of overweight and obesity in 644 patients with bipolar disorder", J Clin Psychiatry, 63, pp.207~213 (2002)
6. McElroy SL, "Are mood disorders and obesity related? A review for the mental health professional", J Clin Psychiatry, 65, pp.634~651 (2004)
7. Hirschfeld RM, "Long-term side effects of SSRIs: sexual dysfunction and weight gain", J Clin Psychiatry, 64(Suppl 18), pp.20~24 (2003)
8. McIntyre RS, "Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities", Can J Psychiatry, 46, pp.273~281 (2001)
9. Nathan PJ, "Neuropsychiatric adverse effects of centrally acting antiobesity drugs", CNS Neurosci Ther, 17, pp.490~505 (2011)
10. Dixon JB, "Depression in association with severe obesity: changes with weight loss", Arch Intern Med, 163, pp.2058~2065 (2003)
11. Fakhoury WK, "Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline", Int Clin Psychopharmacol, 16, pp.153~162 (2001)
12. Gitlin MJ, "Maintenance lithium treatment: side effects and compliance", J Clin Psychiatry, 50, pp.127~131 (1989)
13. Kaplan LM, "Pharmacologic therapies for obesity", Gastroenterol Clin North Am, 39, pp.69~79 (2010)
14. Rothman RB, "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin", Synapse, 39, pp.32~41 (2001)
15. Ioannides-Demos LL, "Pharmacotherapy for obesity", Drugs, 65, pp.1391~1418 (2005)
16. Greenway FL, "Safety of obesity drugs", Expert Opin Drug Saf, 4, pp.1083~1095 (2005)
17. Ioannides-Demos LL, "Pharmacotherapies for obesity: past, current, and future therapies", J Obes, 2011 (2011)
18. John CE, "Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices", Neuropharmacology, 52, pp.1596~1605 (2007)
19. Franken IH, "The role of dopamine in human addiction: from reward to motivated attention", Eur J Pharmacol, 526, pp.199~206 (2005)
20. Taber KH, "Neuroanatomy of dopamine: reward and addiction", J Neuropsychiatry Clin Neurosci, 24, pp.1~4 (2012)
21. Cruickshank CC, "A review of the clinical pharmacology of methamphetamine", Addiction, 104, pp.1085~1099 (2009)
22. Nakagawa T, "Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3,4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N,N-diisopropyltryptamine (foxy)", J Pharmacol Sci, 106, pp.2~8 (2008)
23. Hendricks EJ, "A study of abrupt phentermine cessation in patients in a weight management program", Am J Ther, 18, pp.292~299 (2011)
24. Glatz AC, "Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine", Pharmacol Biochem Behav, 71, pp.197~204 (2002)
25. Alexander M, "Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis", Synapse, 56, pp.94~99 (2005)
26. Moreira R, "The efficacy and tolerability of bupropion in the treatment of major depressive disorder", Clin Drug Investig, 31(Suppl 1), pp.5~17 (2011)
27. "Teva Pharmaceuticals USA. Adipex-P drug label"[URL]
28. Raison CL, "Psychotic mania associated with fenfluramine and phentermine use", Am J Psychiatry, 154, pp.711~ (1997)
29. Bostwick JM, "A toxic reaction from combining fluoxetine and phentermine", J Clin Psychopharmacol, 16, pp.189~190 (1996)
30. Cleare AJ, "Phentermine, psychosis, and family history", J Clin Psychopharmacol, 16, pp.470~471 (1996)
31. Zimmer JE, "Bipolar depression associated with fenfluramine and phentermine", J Clin Psychiatry, 59, pp.383~384 (1998)
32. Douglas A, "Plasma phentermine levels, weight loss and side-effects", Int J Obes, 7, pp.591~595 (1983)
33. Allison DB, "Controlled-release phentermine", topiramate in severely obese adults: a randomized controlled trial (EQUIP), 2012, pp.20, 330~342
34. "Food and Drug Administration. Qsymia (phentermine and topiramate extended-release) capsules approval letter 2012" (2012)[URL]
35. Rosenstock J, "A randomized, doubleblind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients", Diabetes Care, 30, pp.1480~1486 (2007)
36. Nisoli E, "An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action", Obes Rev, 1, pp.127~139 (2000)
37. Halford JC, "Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake", Pharmacol Biochem Behav, 61, pp.159~168 (1998)
38. Connoley IP, "Thermogenic effects of sibutramine and its metabolites", Br J Pharmacol, 126, pp.1487~1495 (1999)
39. "FDA Drug Safety Communication: FDA recommends against the continued use of Meridia (sibutramine)"[URL]
40. Bymaster FP, "Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors", Neuropsychopharmacology, 25, pp.871~880 (2001)
41. Naik S, "Recurrent episodes of brief affective psychosis induced by sibutramine", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.1359~1360 (2010)
42. Cordeiro Q, "Sibutramine-induced mania episode in a bipolar patient", Int J Neuropsychopharmacol, 5, pp.283~284 (2002)
43. Benazzi F, "Organic hypomania secondary to sibutraminecitalopram interaction", J Clin Psychiatry, 63, pp.165~ (2002)
44. Rocha FF, "Hypomanic episode secondary to sibutramine in a patient with type-I bipolar disorder", Rev Bras Psiquiatr, 30, pp.400~401 (2008)
45. Elfhag K, "Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood", Pharmacol Res, 51, pp.159~163 (2005)
46. Kiortsis DN, "Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study", Nutr Metab Cardiovasc Dis, 18, pp.207~210 (2008)
47. "Sibutramine drug label 2010" (2010)[URL]
48. Perrio MJ, "The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England", Obesity (Silver Spring), 15, pp.2712~2722 (2007)
49. McElroy SL, "A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders", Bipolar Disord, 9, pp.426~434 (2007)
50. Shakir SAW, "Prescription-event monitoring, Textbook of pharmacoepidemiology.", pp.203~216 (2005), John Wiley & Sons
51. Faulconbridge LF, "Changes in symptoms of depression with weight loss: results of a randomized trial", Obesity (Silver Spring), 17, pp.1009~1016 (2009)
52. Heal DJ, "What is the prognosis for new centrally-acting anti-obesity drugs?", Neuropharmacology, 63, pp.132~146 (2012)
53. Astrup A, "Topiramate: a new potential pharmacological treatment for obesity", Obes Res, 12(Suppl), pp.167S~173S (2004)
54. Eliasson B, "Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial", Int J Obes (Lond), 31, pp.1140~1147 (2007)
55. "Belviq (lorcaserin hydrochloride) approval letter 2012" (2012)[URL]
56. Stahl SM, "Stahl's essential psychopharmacology: The prescriber's guide" (2011), Cambridge University Press
57. Sachs GS, "A double-blind trial of bupropion versus desipramine for bipolar depression", J Clin Psychiatry, 55, pp.391~393 (1994)
58. Parikh SV, "Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)", Can J Psychiatry, 55, pp.136~143 (2010)
59. Brown ES, "A randomized, double-blind, placebocontrolled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence", Alcohol Clin Exp Res, 33, pp.1863~1869 (2009)

관련 논문AI추천